The development of CAR T-cell technology is a defining moment in the history of biomedicine – one of the all-time amazing transformative breakthroughs

Manufacturing bottlenecks remain a key hurdle in CAR-T therapy. Can automation and digital integration change that?

The IQVIA Institute’s latest report evaluates how well seven countries are prepared to support the complex infrastructure required for CAR T therapies

A look at the FDA’s safety investigation into CAR T therapeutics.

Large study shows secondary tumors after CAR-T cancer therapies are rare

Carl June discusses his pathway into immunology, and the history and success of CAR-T therapy.

The details and reactions behind a recent FDA investigation into the cancer-risk of CAR-T therapies

We sat down with Kite’s Cindy Perettie to talk about access to CAR Ts.

Carl June and UPenn researchers develop next generation CAR T cell therapy and demonstrate promising results in phase I trial.